Lexicon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Lexicon Pharmaceuticals's earnings have been declining at an average annual rate of -42.8%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 70.4% per year.
Key information
-42.8%
Earnings growth rate
-32.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -70.4% |
| Return on equity | -67.0% |
| Net Margin | -8,380.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08
Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Apr 25Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?
Jan 04Lexicon Pharma: Key Regulatory Event In May 2023
Oct 01Lexicon announces FDA review of heart failure therapy
Jul 27Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win
Jul 13Lexicon Pharmaceuticals up 9% on mid-stage study for diabetic neuropathy drug
Jun 29Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Jun 15Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead
May 31Revenue & Expenses BreakdownBeta
How Lexicon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -194 | 127 | 2 |
| 31 Dec 23 | 1 | -177 | 114 | 0 |
| 30 Sep 23 | 1 | -158 | 98 | 0 |
| 30 Jun 23 | 0 | -131 | 78 | 0 |
| 31 Mar 23 | 0 | -110 | 59 | 0 |
| 31 Dec 22 | 0 | -102 | 48 | 0 |
| 30 Sep 22 | 0 | -97 | 41 | 0 |
| 30 Jun 22 | 0 | -97 | 35 | 0 |
| 31 Mar 22 | 0 | -90 | 33 | 0 |
| 31 Dec 21 | 0 | -88 | 32 | 0 |
| 30 Sep 21 | 0 | -68 | 30 | 0 |
| 30 Jun 21 | 7 | 38 | 32 | 0 |
| 31 Mar 21 | 16 | -13 | 38 | 0 |
| 31 Dec 20 | 24 | -59 | 44 | 0 |
| 30 Sep 20 | 33 | -104 | 52 | 0 |
| 30 Jun 20 | 320 | 39 | 57 | 0 |
| 31 Mar 20 | 321 | 85 | 57 | 0 |
| 31 Dec 19 | 322 | 130 | 57 | 0 |
| 30 Sep 19 | 330 | 164 | 59 | 0 |
| 30 Jun 19 | 43 | -89 | 61 | 0 |
| 31 Mar 19 | 47 | -101 | 63 | 0 |
| 31 Dec 18 | 63 | -121 | 64 | 0 |
| 30 Sep 18 | 81 | -126 | 63 | 0 |
| 30 Jun 18 | 101 | -129 | 64 | 0 |
| 31 Mar 18 | 99 | -130 | 66 | 0 |
| 31 Dec 17 | 92 | -123 | 66 | 0 |
| 30 Sep 17 | 80 | -133 | 64 | 0 |
| 30 Jun 17 | 81 | -138 | 60 | 0 |
| 31 Mar 17 | 89 | -141 | 50 | 0 |
| 31 Dec 16 | 79 | -131 | 43 | 0 |
| 30 Sep 16 | 188 | -22 | 36 | 0 |
| 30 Jun 16 | 160 | -22 | 29 | 0 |
| 31 Mar 16 | 141 | -11 | 27 | 0 |
| 31 Dec 15 | 130 | -5 | 24 | 0 |
| 30 Sep 15 | 24 | -94 | 21 | 0 |
| 30 Jun 15 | 24 | -100 | 21 | 0 |
| 31 Mar 15 | 24 | -98 | 19 | 0 |
| 31 Dec 14 | 23 | -100 | 19 | 0 |
| 30 Sep 14 | 3 | -115 | 19 | 0 |
| 30 Jun 14 | 3 | -106 | 19 | 0 |
| 31 Mar 14 | 2 | -109 | 18 | 0 |
| 31 Dec 13 | 2 | -104 | 17 | 0 |
| 30 Sep 13 | 1 | -112 | 18 | 0 |
| 30 Jun 13 | 1 | -109 | 17 | 0 |
Quality Earnings: LXRX is currently unprofitable.
Growing Profit Margin: LXRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LXRX is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare LXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LXRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: LXRX has a negative Return on Equity (-67.01%), as it is currently unprofitable.